Valuation: Plasmatech Biopharmaceuticals Inc

Market Cap 400M 350M 325M 299M 565M 38.24B 576M 3.87B 1.52B 18.78B 1.5B 1.47B 64.85B P/E 2026 *
-9.49x
P/E 2027 * -100x
Enterprise Value 400M 350M 325M 299M 565M 38.24B 576M 3.87B 1.52B 18.78B 1.5B 1.47B 64.85B EV / Sales 2026 *
6.1x
EV / Sales 2027 * 2.96x
Free-Float
79.45%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Plasmatech Biopharmaceuticals Inc

Manager TitleAgeSince
Chief Executive Officer 50 14/10/2021
Director of Finance/CFO 42 13/03/2022
Chief Tech/Sci/R&D Officer - 19/10/2025
Director TitleAgeSince
Director/Board Member 58 28/02/2006
Director/Board Member 64 24/03/2021
Director/Board Member 63 18/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
-0.22%+2.04%+16.79%-8.03% 67.46B
-0.63%-7.39%+37.82%+199.82% 51.13B
+0.36%+40.00%+40.00%+40.00% 43.4B
+1.34%-1.25%-49.33%-53.09% 40.32B
+4.96%+0.27%+55.75%-24.80% 30.86B
-1.85%-18.08%+99.20%-47.07% 26.59B
-2.12%-1.20%+66.54%+84.42% 22.82B
+0.90%+3.04%+9.57%+176.89% 19.79B
-2.12%-3.92%+61.37%+130.60% 16.47B
Average +0.01%-3.63%+37.52%+55.41% 35.43B
Weighted average by Cap. +0.13%-3.05%+31.02%+46.52%

Financials

2026 *2027 *
Net sales 65.51M 57.46M 53.22M 48.97M 92.62M 6.27B 94.42M 634M 249M 3.08B 246M 241M 10.63B 135M 118M 110M 101M 191M 12.92B 194M 1.31B 512M 6.34B 507M 496M 21.9B
Net income -42.25M -37.06M -34.33M -31.58M -59.74M -4.04B -60.9M -409M -160M -1.99B -159M -155M -6.86B -2.1M -1.84M -1.71M -1.57M -2.97M -201M -3.03M -20.34M -7.98M -98.76M -7.89M -7.72M -341M
Net Debt - -
Logo Plasmatech Biopharmaceuticals Inc
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-